Glaukos price target raised to $102 from $90 at BTIG

BTIG raised the firm’s price target on Glaukos to $102 from $90 and keeps a Buy rating on the shares. The stock has risen over 50% since the iDose approval, as Glaukos is doing a good job in progressing towards its milestones, its management has contained expectations for the launch, and nothing has fundamentally changed from the time of approval to now that would throw the company off its trajectory in FY24, the analyst tells investors in a research note.